The cost of GLP-1 RAs must be weighed against the potential of these agents to lower the costs associated with the treatment of diabetes and its complications.36 Our study found that many interventions for DR, including intravitreal injections, panretinal laser photocoagulation, and vitrectomy for DR, were less frequently needed by patients with GLP-1 RA prescriptions compared with those without GLP-1 RA prescriptions. The gene discussed is GLP1R; the disease is diabetes mellitus.